# High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)

> **NCT03217903** · NA · UNKNOWN · sponsor: **Central Hospital, Nancy, France** · enrollment: 32 (estimated)

## Conditions studied

- High-risk Myelodysplastic Syndromes With Excess Blasts

## Interventions

- **DIAGNOSTIC_TEST:** Myelogram

## Key facts

- **NCT ID:** NCT03217903
- **Lead sponsor:** Central Hospital, Nancy, France
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-12
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03217903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03217903, "High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03217903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*